Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Working Capital Changes (2022 - 2025)

Historic Other Working Capital Changes for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$1.4 million.

  • Phathom Pharmaceuticals' Other Working Capital Changes fell 16820.81% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 18586.85%. This contributed to the annual value of $7.7 million for FY2024, which is 489.65% down from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Other Working Capital Changes stood at -$1.4 million, which was down 16820.81% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Other Working Capital Changes registered a high of $5.9 million during Q4 2024, and its lowest value of -$7.8 million during Q1 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' median Other Working Capital Changes value was $254000.0 (recorded in 2023), while the average stood at $664066.7.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first surged by 221811.02% in 2024, then crashed by 164720.36% in 2025.
  • Phathom Pharmaceuticals' Other Working Capital Changes (Quarter) stood at $4.2 million in 2022, then tumbled by 93.88% to $254000.0 in 2023, then surged by 2218.11% to $5.9 million in 2024, then plummeted by 123.64% to -$1.4 million in 2025.
  • Its Other Working Capital Changes stands at -$1.4 million for Q3 2025, versus $1.6 million for Q2 2025 and -$7.8 million for Q1 2025.